한글목차

비결핵성 항산균(NTM)의 주요 7개국(미국, 유럽 5개국, 일본) 시장에 대해 조사했으며, 질환 개요, 시장 매출 예측, 파이프라인 분석, 현재 및 향후 경쟁 분석 등의 정보를 전해드립니다.

목차

제1장 서문

• 컨텐츠
• 약어
• 관련 보고서

제2장 주요 요약

제3장 질환 개요

• NTM 개요
• NTM 시장 SWOT 분석
• NTM 분류
• NTM 위험인자

제4장 역학

• NTM 발병자수, N, 남녀(2023-2033년)
• NTM 유병자수, 남녀, N(2023-2033년)
• NTM, PNTM, DNTM 발병자수, 남녀, N(2023년)
• NTM, PNTM, DNTM 유병자수, 남녀, N(2023년)
• NTM, PNTM, DNTM 발병자수 정보 출처와 조사 방법
• NTM, PNTM, DNTM 유병자수 정보 출처와 조사 방법
• NTM 발병자수/유병자수 정보 출처와 조사 방법
• PNTM 발병자수/유병자수 정보 출처와 조사 방법
• DNTM 발병자수/유병자수 정보 출처와 조사 방법

제5장 현재 치료 옵션

• PNTM 진단 패러다임
• 치료 패러다임
• 현재 치료 옵션

제6장 미충족 수요와 기회

• NTM의 미충족 수요
• 유효성이 향상된 새로운 치료 옵션
• 진단 방법 개량
• 임상시험 개량

제7장 연구개발 전략

• NTM의 임상시험 설계 동향
• NTM의 거래 결정 동향

제8장 파이프라인 평가

• NTM 파이프라인 개요
• NTM용 후기 파이프라인 제품
• NTM 임상시험(단계 II/III) 개요

제9장 시장 전망

• NTM 시장 예측
• PNTM 시장 예측
• DNTM 시장 예측
• 시장 촉진요인과 장벽

제10장 부록

제11장 문의

영문목차

The report provides an assessment of the NTM therapeutics market including disease overview, epidemiology, current treatment options, unmet needs and opportunities, R&D strategies, pipeline assessment, and market outlook.

NTM refers to infection with a group of bacteria within the Mycobacterium genus, which excludes Mycobacterium tuberculosis (tuberculosis) and Mycobacterium leprae (leprosy). NTM infections are noncontagious, opportunistic infections that cause a wide range of clinical disease in patients with pre-existing health conditions or compromised immune systems. ). In terms of global burden, NTM lung disease is relatively uncommon. It is suggested that host defense mechanisms in most healthy individuals are sufficient to prevent or suppress NTM infection. Patients who develop NTM lung disease likely have susceptibility factors such as pre-existing comorbidities that make them vulnerable to these infections.

Key Highlights

• Report deliverables include a Pdf report and an Excel-based forecast model
• Forecast includes the 7 major markets (7MM)
• Forecast covers the period 2023-2033

Scope

• Overview of NTM, including classification, epidemiology, diagnostic and treatment paradigms.
• Annualized NTM therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2023 to 2033.
• Key topics covered include assessment of marketed therapies and pipeline agents, unmet needs, pipeline assessment and market outlook for the US, 5EU, and Japan over the 10-year forecast period.
• Pipeline analysis: Emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
• Analysis of the current and future market competition in the 7MM NTM therapeutics market. Insightful review of the key industry drivers and barriers.

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipelines.
• Develop business strategies by understanding the trends shaping and driving the 7MM NTM therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the NTM therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

Table of Contents

1. Preface

• 1.1. Contents
• 1.2. Abbreviations
• 1.3. Related Reports

2. Executive Summary

3. Disease Overview

• 3.1. Overview of NTM
• 3.2. NTM Market SWOT Analysis
• 3.3. Classification of NTM
• 3.4. NTM Risk Factors

4. Epidemiology

• 4.1. Diagnosed Incident Cases NTM, N, Both Sexes, 2023-33
• 4.2. Diagnosed Prevalent Cases of NTM, Both Sexes, N, 2023-33
• 4.3. Diagnosed Incident Cases of NTM, PNTM, and DNTM, Both Sexes, N, 2023
• 4.4. Diagnosed Prevalent Cases of NTM, PNTM, and DNTM, Both Sexes, N, 2023
• 4.5. Sources and Methodology for Diagnosed Incident Cases of NTM, PNTM, and DNTM
• 4.6. Sources and Methodology for Diagnosed Prevalent Cases of NTM, PNTM and DNTM
• 4.7. Sources and Methodology for Diagnosed Incident and Prevalent Cases of NTM
• 4.8. Sources and Methodology for Diagnosed Incident and Prevalent Cases of PNTM
• 4.9. Sources and Methodology for Diagnosed Incident and Prevalent Cases of DNTM

5. Current Treatment Options

• 5.1. PNTM Diagnostic Paradigm
• 5.2. Treatment Paradigm
• 5.3. Current Treatment Options

6. Unmet Needs and Opportunities

• 6.1. Unmet Needs in NTM
• 6.2. New Therapeutic Options with Improved Efficacy
• 6.3. Improved Diagnostic Methods
• 6.4. Improved Clinical Trials

7. R&D Strategies

• 7.1. Trends in Clinical Trial Design in NTM
• 7.2. Trends in Deal-Making in NTM

8. Pipeline Assessment

• 8.1. NTM Pipeline Overview
• 8.2. Late-Stage Pipeline Products for NTM
• 8.3. NTM Clinical Trials (Phase II/III) Overview

9. Market Outlook

• 9.1. NTM Market Forecast
• 9.2. PNTM Market Forecast
• 9.3. DNTM Market Forecast
• 9.4. Market Drivers and Barriers

10. Appendix

• 10.1. Primary Research: KOL Information
• 10.2. Bibliography
• 10.3. About the Authors

11. Contact Us